Subscribe
With additional JAK inhibitors under exploration in the myelofibrosis pipeline, such as momelotinib and pacritinib, FDA-approved options continue to be utilized heavily in the paradigm, explained John O. Mascarenhas, MD.
FDA Approval Sought for Pacritinib to Treat Myelofibrosis With Severe Thrombocytopenia
Genetic Testing Improves Treatments, Outcomes in MPNs and MDS
FDA Approves Fedratinib for Patients With Myelofibrosis
FDA Grants Fast Track to Momelotinib to Treat Myelofibrosis
